Jaw Osteonecrosis a Risk Factor in Bisphosphonate Therapy - A Dental Concern
Manpreet S Walia, Saryu Arora, Bhawana Singal
Citation Information :
Walia MS, Arora S, Singal B. Jaw Osteonecrosis a Risk Factor in Bisphosphonate Therapy - A Dental Concern. J Oral Health Comm Dent 2010; 4 (3):72-77.
Bisphosphonates are compound used in the treatment of many skeletal disorders such as bone metastases, osteoporosis, Paget's disease, hypercalcaemia of malignancy and bone pain. A new complication of bisphosphonate therapy administration i.e. osteonecrosis of jaw also known as bisphosphonate related osteonecrosis of the jaws seems to be developing. Over suppression of bone turn over is probably the primary mechanism for the development of this condition, although there may be contributing comorbid factors. Complete prevention of this complication is not currently possible. However, preventive dental care reduces this incidence. Conservative debridement of necrotic bone, pain control, infection management, use of antimicrobial oral rinses and withdrawal of bisphosphonates are preferable to aggressive surgical measures for treating this condition.
Oral biphosphonate use and the prevalence of osteonecrosis of the jaw: An institutional inquiry. J Am Dent Assoc 2009;140:61–66.
Dental Side Effects of Oral Bisphosphonates. Drug Review 2008;13(11): 21–22.
Clinical application of bisphosphonates in implant dentistry: histomorphometric evaluation. Int J Periodontics Restorative Dent 2009;29(1):31–39.
Bisphosphonates: mechanisms of action. Endocr Rev 1998;19:80–100.
Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporos Int 1999;9(Suppl 2):S66–80.
Pharmacokinetics of alendronate: an overview. Int J Clin Pract Suppl 1999;101:18–26.
Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000;88:1082–1090.
Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001;91:1191–2000.
Clinical benefit of zoledronic acid for the prevention of skeletal complications in advanced prostate cancer. Clin Prostate Cancer 2005;4:31–37.
Osteonecrosis of the jaw in cancer after treatment with bisphosphonates : incidence and risk factors. J Clin Oncol 2005;23(34):580–587.
Nature and frequency of bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 2009;36(3):478–90.
Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63:1567–75.
Physical and chemical injury. In: Oral and maxillofacial pathology 3rd ed. St. Louis, Missouri: Elsevier Inc. 2009:pp.285–329.
Oral bisphophonate inuced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention and treatment. J Oral Maxillofac Surg 2007;65(12): 2397–2410.
Bisphosphonate associated jaw bone osteonecrosis: a correlation between imaging techniques and histopathology. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008;105(3):358–364.
